ArticleGastro hep advances2026
Clinical, Serologic, and Histologic Characteristics in Screen-Detected and Clinically Diagnosed Celiac Disease Patients.
Article in Gastro hep advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and Aims: The benefits of celiac disease screening remain debatable. We compared baseline characteristics and treatment outcomes between screen-detected and clinically diagnosed celiac disease adults in a prospective study. Methods: Clinical, serologic, and histologic data and bone mineral density (BMD) were assessed in 214 patients at diagnosis and after 1 year on gluten-free diet (GFD). Validated questionnaires were used to elicit gastrointestinal symptoms (Gastrointestinal Symptoms Rating Scale) and quality of life (Psychological General Well-Being questionnaire). Results: Screen-detected patients (n = 102) were older (median, 54 vs 43 years; Conclusion: Screen-detected celiac disease patients demonstrated less severe symptoms and BMD impairment at diagnosis but advanced histologic and serologic disease similar to those identified on clinical grounds. Adherence to GFD and treatment response were comparable between the groups.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.